SHINECO, INC.: M&A transaction — Shineco closes 51% acquisition of InfiniClone for ~$19.9M cash and 3.45M shares

SHINECO, INC.

Acquired 51% equity in InfiniClone Limited from Dr. Lim Kah Meng.
Consideration: $19,895,600 cash plus 3,450,000 shares of common stock.
Shares issued under Regulation S; seller represented non-U.S. person status.
Financial statements and pro forma data to be filed within 71 days.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

SHINECO, INC. completed an acquisition involving Dr. Lim Kah Meng for US$19,895,600 in cash and 3,450,000 shares (closed 2025-06-18).

Action: acquisition
Counterparty: Dr. Lim Kah Meng
Consideration: US$19,895,600 in cash and 3,450,000 shares
Closing: 2025-06-18

Exact text from the filing

in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life Science. In exchange, Shineco Life Science paid to the Seller US$19,895,600 in cash and the Company issued 3,450,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”). The Shares were issued in reliance on Rule 902 of

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001641172-25-016061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.